Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on tumor infiltrating lymphocyte (TIL) cell therapies for cancer. These documents offer detailed insight into the company’s financial condition, capital structure, product commercialization, and clinical and regulatory activities.
Iovance’s current reports on Form 8-K, for example, describe quarterly financial results, updates on clinical and commercial progress for Amtagvi and Proleukin, corporate presentations used at healthcare conferences, and material agreements such as an amended and restated open market sale agreement that enables at-the-market offerings of common stock. Other 8-K filings outline executive leadership changes and report press releases related to regulatory milestones, including the approval of Amtagvi in Canada for advanced melanoma after anti-PD-1 and targeted therapy.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing every technical detail. Real-time updates from the EDGAR system ensure that new filings, such as earnings-related 8-Ks, registration statements, or material financing agreements, appear promptly.
Users can also review filings that touch on equity compensation plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4), which shed light on how Iovance uses stock-based incentives. Together, the full-text filings and AI-generated explanations offer a structured view of how Iovance reports its operations, risk factors, and strategic decisions to regulators and investors.
GRAF FINCKENSTEIN FRIEDRICH reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest over three years, assuming continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years. After this grant, the reporting person holds 58,750 RSUs directly.
Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Kirby received a grant of 132,200 restricted stock units. Each RSU represents a contingent right to receive one share of common stock. After this grant, he holds 132,200 RSUs.
The RSUs vest over three years if he remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years.
BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.
Iovance Biotherapeutics reported that Chief Operating Officer Igor Bilinsky received a grant of 117,500 restricted stock units. Each RSU represents one share of common stock. The award vests over three years, with one-third vesting after one year and the balance in eight quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. interim CEO and General Counsel Frederick G. Vogt reported equity compensation-related transactions. On March 5, 2026, 62,493 restricted stock units (RSUs) vested, converting into 62,493 shares of common stock at a stated price of $0.00 per share.
The company withheld 26,755 common shares at $4.58 per share to cover mandatory tax withholding on the RSU vesting, which is described as not an open market sale. After these transactions, Vogt directly owned 529,538 shares of common stock and 125,007 RSUs from the referenced grant.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 5, 2026, 31,246 RSUs vested, each converting into one share of common stock at a stated price of $0.00 per share.
Following the RSU vesting and conversion, 16,520 common shares were withheld by the company at $4.58 per share to satisfy mandatory tax withholding requirements, which the disclosure specifies is not an open market sale. After these transactions, Graf Finckenstein directly owned 131,957 shares of common stock and 62,504 RSUs from this grant, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported equity compensation activity involving restricted stock units and common stock. On the transaction date, 39,059 restricted stock units vested, each representing a right to receive one share of common stock, and were converted into 39,059 shares of Iovance common stock.
To cover mandatory tax withholding on the vesting, 18,360 shares of common stock were withheld by the company at a price of $4.58 per share. This withholding was not an open market sale of securities. After these transactions, Puri directly held 239,230 shares of common stock and 78,131 restricted stock units, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported the vesting of 31,246 restricted stock units on March 5, 2026, which were converted into an equal number of common shares at no exercise price.
To cover mandatory tax withholding on this RSU vesting, 16,628 common shares were withheld by the company at a reference price of $4.58 per share, which the disclosure states is not an open market sale. After these transactions, Bilinsky directly held 125,766 common shares and 62,504 RSUs. The remaining RSUs from this March 5, 2025 grant are scheduled to vest in equal quarterly installments, with each unit representing the right to receive one share of common stock.
IOVANCE Biotherapeutics interim CEO and General Counsel Frederick G. Vogt reported vesting of restricted stock units and related tax withholding. On March 2, 2026, RSUs covering 52,087 shares of common stock vested and were delivered at no cost through derivative exercises.
The company then withheld 22,809 common shares at $3.79 per share to cover mandatory tax obligations, which the filing clarifies was not an open market sale of securities. After these transactions, Vogt directly owned 493,800 shares of common stock, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported equity award activity tied to restricted stock units. On March 2, 2026, RSUs covering 8,790 and 3,517 shares vested and were converted into common stock at no cash exercise price. This resulted in the issuance of 12,307 shares of common stock. Separately, 6,903 shares of common stock were withheld by the company to cover mandatory tax obligations upon vesting, which the filing notes was not an open market sale. After these transactions, Bilinsky directly owned 111,148 shares of common stock.
IOVANCE BIOTHERAPEUTICS, INC. Chief Regulatory Officer Raj K. Puri reported the vesting of 5,470 restricted stock units (RSUs), which converted into an equal number of common shares on March 2, 2026. Each RSU represents a contingent right to receive one share of common stock.
To cover mandatory taxes on this vesting, the issuer withheld 2,798 common shares at $3.79 per share in a tax-withholding disposition that was not an open market sale. Following these transactions, Puri directly held 218,531 shares of common stock and 21,878 RSUs remaining from a March 1, 2024 grant that will vest in equal quarterly installments.